The multi-centre, open-label, early stopping design study will measure the clinical activity of Tasquinimod by the section of patients with progression free survival at pre-defined time-points.
Ipsen R&D executive vice-president and chief scientific officer Claude Bertrand said tasquinimod should be assessed beyond prostate cancer due to its unique mode of action.
"We hope that this innovative, proof-of-concept study in oncology will generate data on tasquinimod’s biological and clinical activity and safety profile supporting further clinical development in high unmet medical need diseases," Bertrand added.
Tasquinimod’s immunomodulatory and anti-angiogeneic properties are applicable in addressing unmet medical need in a range of carcinomas, according to the company.